Interpace Diagnostics

Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT®

Interpace Biosciences Announces New Draft LCD and Reimbursement for Its Proprietary Thyroid Assay, ThyGeNEXT® Interpace Biosciences is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Since our founding,…

Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China https://bit.ly/2DUgunz

Interpace Biosciences Expands Strategic Partnership Activities with Genecast Biotechnology in China Interpace Biosciences is a dynamic and growing leader in the life sciences industry, providing complex molecular analysis for the early diagnosis and treatment of cancer and supporting the development of targeted therapeutics. Since our founding,…

Interpace Biosciences Launches New Corporate Website

Interpace Biosciences Launches New Corporate Website Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace Diagnostics updated their business hours.

Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results https://bit.ly/2KlQh55

Interpace Diagnostics Changes Name to Interpace Biosciences; Announces Plans for Next Phase of Growth and Third Quarter 2019 Financial Results Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it will report its third quarter 2019 financial results on Wednesday, November 13, 2019 at 4:30 p.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and provide a general business update. For more information:

Interpace to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results on Wednesday, November 13, 2019 Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today the publication of two peer-reviewed journal articles and one textbook chapter supporting the clinical utility of ThyGeNEXT® when used alone and in combination with ThyraMIR®. According to Jack Stover, Interpace’s CEO, “These publications provide further evidence of the clinical utility of our molecular products for thyroid cancer.” In addition, he stated, “our accumulation of data helps validate our claims with insurance companies who are effectively the gate keepers for patients needing our expertise.” Read today's press release for more information:

Interpace Diagnostics Announces Publication of New Data on Thyroid Test Utility Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it will be presenting new data on the performance of its molecular thyroid products at the upcoming 89th Annual Meeting of the American Thyroid Association (ATA), being held October 30th to November 3rd, 2019 in Chicago, IL. The ATA meeting is one of the largest gatherings of endocrinologists, ENT’s, surgeons and other providers who focus on the diagnosis and treatment of thyroid cancer. Interpace will be presenting three separate posters focused on the performance of the company’s molecular tests for indeterminate thyroid nodules, ThyGeNEXT® and ThyraMIR®. For more information: https://bit.ly/2WpILen

Interpace to Present Data at the ATA Annual Meeting Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it will be presenting new data on the performance of its GI products at the American College of Gastroenterology Conference being held on October 27-30 in San Antonio, Texas. For more information:

Interpace to Present at the American College of Gastroenterology Conference Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners

Interpace Announces Closing of $13 Million Second Tranche Acquisition Financing from Ampersand Capital Partners Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has been named one of the 50 Most Admired Companies of the Year by The Silicon Review. The honorees are chosen by The Silicon Review’s editorial board recognizing companies whose industry achievements break new technological ground and who’s company cultures and values represent a commitment to innovation.

Interpace Named to ‘Most Admired Companies’ List Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has contracted with 3 independent Blue Cross Blue Shield (BCBS) plans totaling nearly 5 million covered lives across Alabama, Arkansas, and Arizona. These members of the BCBS Association are the largest payers in their respective states and each affiliate’s customers now have access to both the ThyGeNEXT® and ThyraMIR® tests for assessing indeterminate thyroid biopsies on an in-network basis.

Interpace Announces New Contracts with Multiple Blue Cross Blue Shield Plans Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace President and CEO, Jack Stover, will present at the upcoming Ladenburg Thalmann 2019 Healthcare Conference at the Sofitel Hotel, NYC on Tuesday, September 24th at 9am EST. Mr. Stover will provide an overview of the business and will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference.

Interpace to Present at The Ladenburg Thalmann 2019 Healthcare Conference Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace today announced that it has entered into a partnership agreement to jointly develop, promote, and offer translational studies and clinical trial solutions to biotech and pharmaceutical companies with Genecast (Beijing) Biotechnology Co. Ltd (“Genecast”) of the Peoples Republic of China (“PRC”). Genecast is a leader in offering diagnostic products and services in the field of oncology and providing a wide range of diagnostic services to pharmaceutical and biotech companies in the PRC. According to the agreement, Interpace BioPharma will perform services worldwide except in the PRC, while Genecast will provide services in the PRC. Learn more:

Interpace Enters Strategic Partnership Agreement with Genecast Biotechnology to Partner with Biopharma Solutions in China Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace today announced that the Company will present at the upcoming 21st Annual Global Investment Conference, sponsored by H.C. Wainwright & Co., held September 8 - 10, 2019 at the Lotte New York Palace Hotel. Jack Stover, President and CEO of Interpace, will provide an overview of the business on Monday, September 9th at 4:15pm EST and will be available to participate in one-on-one meetings with investors and analysts who are registered to attend the conference.

Interpace to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

MD&DI's Jenevieve Blair Polin wrote about Interpace's recent agreement with Helomics to enhance the diagnosis of thyroid cancer via AI-driven analysis. “Helomics has developed an AI bioinformatic platform, known as “D-CHIP,” while Interpace has collected an impressive cache of clinical data from next-generation sequencing (NGS) and microRNA testing of thyroid tumor samples from its combination ThyGeNEXT panel and ThyroMIR classifier. By analyzing the Interpace datasets on the D-CHIP platform, Helomics and Interpace plan to improve diagnosis of thyroid cancer and identify druggable targets.” Read the article here:

AI Mines Clinical Data for Thyroid Cancer Therapeutic Targets An artificial intelligence powerhouse and a leader in molecular diagnostics have teamed up to increase the precision of thyroid cancer diagnosis and minimize unnecessary treatment.

Interpace has been named “Most Innovative Molecular Diagnostics Company 2019 – Northeast USA” as part of Acquisition International Magazine's Global Excellence Awards 2019. https://bit.ly/2N0nQM7

Issue 8 2019 Welcome to the August issue of Acquisition Intl. magazine! Your go-to-source for all of the latest news and features from throughout world of corporate finance. In this month’s edition, we have filled it with insightful articles and features on a vast range of topics as we discover more about mark...

Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update

Interpace Diagnostics Reports Second Quarter 2019 Financial Results and Provides Business Update Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it will report its second quarter 2019 financial results on Tuesday, August 13, 2019 at 8:30 a.m. ET. Interpace will host a conference call and webcast to discuss the Company’s financial results and provide a general business update. Dial-in and webcast details available here:

Interpace Diagnostics to Host Conference Call and Webcast to Discuss Second Quarter 2019 Financial Results on Tuesday, August 13, 2019 Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has contracted with Blue Cross Blue Shield (BCBS) of Michigan, a not-for-profit independent member of the Blue Cross Blue Shield Association with 4.5 million members in the State of Michigan, making it the largest payer in the State, along with another 1.6 million members across multiple other States. The contract makes the ThyGeNEXT® and ThyraMIR® tests both covered services as well as in-network services for their total of 6 million members. As a result of this Agreement, members of BCBS of Michigan’s plans will be able to access Interpace’s molecular thyroid tests on an in-network basis, which will limit their out of pocket expenses in accordance with their in-network benefit levels. Interpace has successfully achieved positive medical coverage for its services through Medicare as well as other leading National and Regional health plans and is now contracting with them. Learn more:

Interpace Diagnostics Announces Contract with Blue Cross Blue Shield of Michigan Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has entered in to a contract with Blue Shield of California, a not-for-profit independent member of the Blue Cross Blue Shield Association making ThyGeNEXT and ThyraMIR tests in-network services for their 4 million lives. Blue Shield originally granted coverage for ThyGeNEXT and ThyraMIR in March of 2018 and now members will be able to access Interpace’s molecular thyroid tests on an in-network basis, which will limit their out of pocket expenses and optimize their benefits in accordance with their in-network benefit levels. According to Jack Stover, CEO of Interpace, “Adding Blue Shield of California under contract and as an in-network provider is beneficial to both the Blue Shield of California members as well as Interpace and represents another milestone in solidifying our molecular thyroid products’ place in the market.” Learn more:

Interpace Announces Contract with Blue Shield of California for ThyGeNEXT® & ThyraMIR® Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has reached an agreement with SelectHealth (a plan associated with Intermountain Healthcare) to provide its proprietary thyroid cancer assays, ThyGeNEXT® and ThyraMIR® to SelectHealth’s more than 850,000 members in Utah and Idaho. Details:

Interpace Announces New Agreement with SelectHealth Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has executed an agreement with the Helomics division of Predictive Oncology (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery. As part of this agreement, the Companies expect to develop a pipeline of products that work seamlessly together to diagnose and assess the risk for thyroid cancer as well as provide appropriate therapeutic recommendations by leveraging Interpace’s Thyroid products, ThyGeNEXT® and ThyraMIR®, coupled with Helomics’ patient-derived tumor profiling and AI platform known as “D-CHIP.” Details:

Interpace Diagnostics Enters Agreement with Predictive Oncology to Enhance Diagnosis of Thyroid Cancer Via AI-Driven Analysis Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace announced today that it has acquired assets and certain liabilities constituting the Biopharma Services business of Cancer Genetics, Inc. (NASDAQ: CGIX) (the “BioPharma Business”) for approximately $23.5 million subject to certain adjustments. The acquisition is expected to create a leading oncology testing and service company in the clinical diagnostic and Biopharma markets, leveraging sophisticated assays, novel algorithms and custom service capabilities across the continuum of oncology from precancerous assessment to drug discovery and clinical trial support. Interpace will hold a conference call and webcast on Tuesday, July 16, 2019 at 8:30am ET to discuss today’s announcement. Full details:

Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners

Interpace Diagnostics Acquires Cancer Genetics’ Biopharma Services Business Supported by Investment from Ampersand Capital Partners Interpace Diagnostics is focused on developing and commercializing molecular diagnostic tests, leveraging the latest technology and personalized medicine for better patient diagnosis and management. The company currently has four…

PancraGEN® is a unique, DNA-based, integrated molecular pathology test that assesses the risk of cancer in pancreatic cysts, helping you to optimally manage each individual patient. Learn how it works here:

How it Works How PancraGEN Works PancraGEN is a cutting edge, proprietary integrated molecular pathology test that assesses the cumulative DNA mutations in key oncogenes and tumor suppressor genes associated with pancreatic cancer. PancraGEN can help assess risk of malignancy in patients with cysts and enhance y...

Interpace's combination testing platform allows ThyGeNEXT and ThyraMIR to work together, providing accurate reclassification for an 85% reduction in unnecessary surgeries for thyroid nodules. Learn more here:

Home - ThyGeNEXT® + ThyraMIR® ThyGeNEXT + ThyraMIR is a rule-in / rule-out testing platform that greatly improves risk stratification of thyroid nodules.

Our new PancraGEN® report format that will launch this July will be quicker to read and comprehend, provide an “at-a-glance” patient-specific test result summary, and define the PancraGEN® interpretive components algorithm.

Interpace's new report for PancraGEN® that will launch in July will include a description of the molecular alterations tested and their implications for pancreatic cancer.